Bio-Rad Labs (BIO) Tops Q2 EPS by 37c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/29/2026
- Wall Street ends higher as Fed holds key rate steady, focus turns to earnings
- SK Hynix shares surge after Q3 profit beats expectations
- Oil prices rise on Yemen fighting, Saudi refinery attack
- Alphabet stock rises as OpenAI plans to buy Google's TPUs
- Wendy's shares surge 16% on $1.4 billion takeover bid by Nelson Peltz’s Trian Fund
- ServiceNow (NOW) Misses Q3 EPS by 2c, Beats on Revenue; Offers Q4 Revenue Guidance
- Oracle sets $225 billion revenue target for FY30 at investor day
- Rivian shares slip ahead of Thursday earnings release
- Marvell in advanced talks to acquire Lumentum, Bloomberg reports
- SpaceX stock drops amid spaceport lawsuit, debt concerns
Bio-Rad Reports Second-Quarter 2018 Financial Results
August 7, 2018 4:49 PM EDTHERCULES, Calif.--(BUSINESS WIRE)-- Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced financial results for the second quarter ended June 30, 2018.
Second-quarter 2018 net sales were $575.9 million, an increase of 14.1 percent compared to $504.7 million reported for the second quarter of 2017. On a currency-neutral basis, quarterly sales increased 11.0 percent compared to the same period in 2017, reflecting broad growth across the business. Second-quarter gross margin was 52.4 percent compared to 54.2 percent during the second quarter in 2017. The decline in gross margin versus the same period last year is the... More



